Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Jun 22 2011

Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica (pregabalin) compared to placebo. Further analysis will be conducted on these initial results.

Central Neuropathic Pain is a heterogeneous group of pain conditions initiated or caused by a primary lesion in the central nervous system and occurs often following spinal cord injury.

"We are pleased with the top-line results of this study and look forward to more fully understanding the benefit that Lyrica may bring to these patients," said Steven J. Romano, M.D., senior vice president, Head, Medicines Development Group, Global Primary Care Business Unit, Pfizer, Inc.

Study A0081107 was a randomized, double-blind, placebo-controlled, parallel group, multi-center study comparing pregabalin flexibly dosed (150-600mg/day, dosed twice-daily) and placebo in subjects with chronic Central Neuropathic Pain following traumatic spinal cord injury. A total of 220 subjects were enrolled in the study (112 pregabalin and 108 placebo) in 66 investigative sites in 10 countries. The primary endpoint was the duration adjusted average change (DAAC), which is a weighted average of change in pain scores based on the duration a subject participated in the study. The preliminary results of the study indicate that the most common adverse events in Lyrica-treated patients were somnolence, dizziness, edema, fatigue, dry mouth, insomnia and blurred vision.